Obatoclax
Obatoclax is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target apoptosis regulator Bcl-2, induced myeloid leukemia cell differentiation protein Mcl-1, and bcl-2-like protein 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | — | — | 2 | 2 | 1 | — | — | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 4 | 3 | — | — | — | 5 |
| Leukemia | D007938 | — | C95 | 3 | 1 | — | — | 1 | 5 |
| Recurrence | D012008 | — | — | 3 | 1 | — | — | — | 3 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 3 | 1 | — | — | — | 3 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 2 | — | — | — | 3 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 3 | 2 | — | — | — | 3 |
| Lung neoplasms | D008175 | — | C34.90 | 3 | 3 | — | — | — | 3 |
| Neoplasms | D009369 | — | C80 | 3 | 1 | — | — | — | 3 |
| Hodgkin disease | D006689 | — | C81 | 1 | 1 | — | — | — | 2 |
| B-cell lymphoma marginal zone | D018442 | — | C88.4 | 2 | 1 | — | — | — | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | — | — | — | — | 4 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 2 | — | — | — | — | 2 |
| Prolymphocytic leukemia | D015463 | — | — | 1 | — | — | — | — | 1 |
| Mycoses | D009181 | — | B35-B49 | 1 | — | — | — | — | 1 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Sezary syndrome | D012751 | — | C84.1 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| T-cell lymphoma | D016399 | — | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia chronic-phase | D015466 | — | — | 1 | — | — | — | — | 1 |
Show 15 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Obatoclax |
| INN | obatoclax |
| Description | Obatoclax mesylate, also known as GX15-070, is an experimental drug for the treatment of various types of cancer. It was discovered by Gemin X, which was acquired by Cephalon, which has since been acquired by Teva Pharmaceuticals. Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.
|
| Classification | Small molecule |
| Drug class | bcl-2 (B-cell lymphoma 2) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C |
Identifiers
| PDB | — |
| CAS-ID | 803712-67-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL408194 |
| ChEBI ID | — |
| PubChem CID | 11404337 |
| DrugBank | — |
| UNII ID | QN4128B52A (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,336 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use